Sign In
Buy SANA
$3.13
-0.120 (-3.69%)
At Close: Jul 31, 2026
Sana Biotechnology Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares
04:05pm, Wednesday, 20'th Aug 2025
SEATTLE, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that
Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
02:58pm, Friday, 08'th Aug 2025
Sana's allogeneic HIP technology achieved a first in T1D, showing insulin production and immune evasion without immunosuppression, but scalability remains unproven. Despite promising early data, Sana
Sana Biotechnology Announces Pricing of Public Offering
11:24pm, Wednesday, 06'th Aug 2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:38pm, Wednesday, 06'th Aug 2025
SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:00am, Wednesday, 06'th Aug 2025
Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (a
Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
04:05pm, Monday, 09'th Jun 2025
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-mont
Sana Biotechnology to Present at June 2025 Investor Conferences
04:05pm, Wednesday, 28'th May 2025
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
04:20pm, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed aga
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
10:15am, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securiti
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 202
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officer
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
07:15am, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securiti
